Pioglitazone reduces central obesity in polycystic ovary syndrome women

Asadipooya, Kamyar; Kalantarhormozi, Mohammadreza; Nabipour, Iraj

doi:10.3109/09513590.2011.583958

Cited by 6 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The metformin-treated patients showed a reduction in the W/H ratio, which contradicts the findings of Morin-Papunen et al, in which waist to hip ratio remained the same after treatment 19 and similar results occurred in the Pioglitazone-treated group reported by Asadipooya and colleagues 20 .…”

Section: Resultscontrasting

confidence: 64%

Outcomes of Pioglitazone and Metformin on Anthropometric, Metabolic and Endocrine variables in POS

Khan¹,

Arslaan²,

Pahore³

et al. 2023

PJMHS

View full text Add to dashboard Cite

Aim: To evaluate the outcomes of Pioglita zone and Metformin on anthropometric, metabolic and endocrine variables in PCOS. Methods: This randomized controlled trial was executed at Pharmacology Department of Bahria University Medical and Dental College in collaboration with Mamji Hospital Karachi from September 2018 to March 2019. Eighty PCOS infertile patients as per Rotterdam 2003 criteria,aged 20-40 years were enrolled. They were divided into two groups of 40 patients each by using computer generated numbers. All patients had fasting insulin levels of >9 μU/mL, serum glucose levels ≥126 mg/dl and suffering from oligomenorrhoea or amenorrhoea. Group A received Tablet Pioglitazone 30 mg once daily and group B was given tablet Metformin 500 mg for three months along with lifestyle changes. Results: Sixty-one participants completed the study. Anthropometric variables included weight, BMI and W/H ratio. Metformin treated group reduced more weight and BMI as compared to Pioglitazone. Metabolic variables included glycaemic indices, lipid profile and hs-CRP estimation. Pioglitazone group improved glycaemic indices more compared to Metformin. Serum progesterone level was significantly increased in Pioglitazone group (5.20±1.18) than Metformin group. Pioglitazone produced more ovulation in comparison to Metformin. Hence it is proved that it is better option in those patients who are unable to tolerate Metformin and cannot continue treatment for infertility. Conclusion: Pioglitazone group produced highly significant increase in serum progesterone level indicating ovulation and improved insulin resistance than the metformin group. Keywords: Female infertility, ovulation induction, Metformin, Pioglitazone, polycystic ovarian syndrome

show abstract

Section: Resultscontrasting

confidence: 64%

Outcomes of Pioglitazone and Metformin on Anthropometric, Metabolic and Endocrine variables in POS

Khan¹,

Arslaan²,

Pahore³

et al. 2023

PJMHS

View full text Add to dashboard Cite

show abstract

“…It also decrease fatty acid release, suppress gluconeogenesis and reduce tumor necrosis factor a disruption of insulin activity [49]. Along with a reduction in insulin resistance, these agents also significantly reduce the central obesity in DM, a common trait found in PCOS also [50,51]. Although, effective in induction of ovulation and regularising the menstruation in PCOS patients [52,53], it has its limitations in women seeking pregnancy, where metformin stands out to be a better and safer alternative [52].…”

Section: Discussionmentioning

confidence: 99%

Predictors of Insulin Resistance and Metabolic Complications in Polycystic Ovarian Syndrome in an Eastern Indian Population

et al. 2012

View full text Add to dashboard Cite

The purpose of this study was to assess the predictive values of central obesity and hyperandrogenemia in development of insulin resistance and dyslipidemia in the polycystic ovarian syndrome (PCOS) patients in our region. Differences of fasting blood glucose level, insulin resistance index HOMA-IR, lipid parameters, waist hip ratio (WHR), body mass index, LH/FSH ratio and testosterone levels between 45 PCOS cases and 35 age matched controls were obtained. Strength of association between different parameters in the case group was assayed by Pearson's correlation analysis. Dependence of insulin resistance and WHR on different predictors was assessed by multiple linear regression assay. Total cholesterol, LDL cholesterol, LH, FSH, LH/FSH ratio, WHR and insulin resistance were significantly higher in the case group (p \ 0.05). Serum testosterone showed strong correlation with insulin resistance and LH/FSH ratio (r = 0.432 and 0.747, p = 0.01 and 0.001 respectively) in the PCOS patients while WHR and serum testosterone level stood out to be most significant predictors for the insulin resistance (b = 0.361 and 0.498; p = 0.048 and 0.049 respectively). Hyperandrogenemia and central obesity were the major factors predicting development of insulin resistance and its related metabolic and cardiovascular complications in our PCOS patients. We suggest early monitoring for androgen level and WHR in these patients for predicting an ensuing insulin resistance and modulating the treatment procedure accordingly to minimise future cardiovascular risks.

show abstract

“…61 The 63,64 Recent studies have demonstrated lower GIP levels in obese women with PCOS. 65,66 Given that insulin resistance is of pathophysiological relevance to the endocrine and metabolic dysfunction of PCOS, the therapeutic benefit of incretin therapy in this population is plausible.…”

Section: Thiazolidinedionesmentioning

confidence: 99%

Advances in Treatment Options for Polycystic Ovary Syndrome

Lathief¹,

Pal²

2012

US Endocrinology

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is the most common endocrinopathy seen in women of reproductive age. Clinical concerns relating to PCOS range from ovulatory infertility and menstrual disorders to risk of diabetes and cardiovascular disease. Hormonal contraceptives have been the mainstay of the management of common PCOS symptoms, such as menstrual irregularity and clinical stigmata of androgen excess (i.e., hirsutism and acne). An appreciation of the relevance of metabolic pathways in the pathophysiology of PCOS is relatively recent, and has translated into an expansion of the therapeutic strategies available for the management of PCOS.Insulin sensitizers were one of the first metabolic modulators to be incorporated in the clinical management paradigm, albeit with mixed results. Recognizing that insulin resistance is central to the pathophysiology of PCOS, newer agents-e.g., thiazolidinedionesfollowed, with almost comparable efficacy to metformin. Statins and most recently incretins constitute novel therapies with distinct metabolic targets that seem to hold promise in the management of PCOS. In tandem with the expansion in pharmaceuticals, a host of complementary and alternative medical therapies have generated interest for purported promise in the management of PCOS, including vitamin D, acarbose, and myo-inositol. The therapeutic options for managing PCOS-related infertility have also expanded. Clomiphene citrate (CC) has long been the first-line strategy for ovulation induction in the setting of anovulatory infertility; however, aromatase inhibitors are fast gaining acceptance as an ovulation induction strategy, with results comparable or even better than those seen with CC. An increasing level of therapeutic sophistication is reflected in ovarian stimulation protocols judiciously using gonadotropins, gonadotropin-releasing hormone antagonists, the procedure of ovarian drilling, and assisted reproductive technologies with in vitro oocyte maturation. KeywordsPolycystic ovary syndrome, androgen, oral contraceptive, antiandrogen, spironolactone, finasteride, flutamide, eflornithine, insulin, metformin, thiazolidinediones, incretins, statins, acarbose, myo-inositol In this article, the authors have attempted to provide an overview of the treatment options that offer therapeutic benefit in PCOS. Treatment Options for Targeting Common Symptoms Combined Oral ContraceptivesHaving long been used as the first-line treatment in PCOS management, combined oral contraceptives (COCs) offer not just menstrual regulation and endometrial protection, but also a benefit against cutaneous stigmata of hyperandrogenism in women with PCOS. 5-7Mechanisms whereby COCs mediate improvements in PCOS-related symptoms include:• a suppression of pituitary luteinizing hormone (LH), thereby reducing the stimulant effect of LH on androgen production by the ovarian theca cells;• an increase in hepatic sex hormone binding globulin (SHBG) directly resulting from the estrogen component in the COC; the net effect is a

show abstract

Pioglitazone reduces central obesity in polycystic ovary syndrome women

Abstract: Pioglitazone has beneficial effects on central obesity of the patients with polycystic ovary syndrome but other clinical consequences of the syndrome may not improve with the drug.

Cited by 6 publications

References 23 publications

Outcomes of Pioglitazone and Metformin on Anthropometric, Metabolic and Endocrine variables in POS

Outcomes of Pioglitazone and Metformin on Anthropometric, Metabolic and Endocrine variables in POS

Predictors of Insulin Resistance and Metabolic Complications in Polycystic Ovarian Syndrome in an Eastern Indian Population

Advances in Treatment Options for Polycystic Ovary Syndrome

Contact Info

Product

Resources

About